Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that Mardi C. Dier has been appointed Chief Financial Officer.
Who to call at Madrigal Pharmaceuticals, and when
A new leader at Madrigal Pharmaceuticals brings new priorities and often new vendors. The first weeks are when they listen.
An alert the day Madrigal Pharmaceuticals raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Madrigal Pharmaceuticals, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Madrigal Pharmaceuticals
Location
Conshohocken, Pennsylvania, United States
About
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH). The Company is focused on entering its next phase of expansion and growth as it ramps up for the launch of resmetirom and continues to build a more fully integrated organization.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Madrigal Pharmaceuticals changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
ConshohockenBiotechnologyHealthcareHealth CareTherapeuticsPharmaceuticalBiopharma